top of page

Free Biopharma Daily Stock Updates - 07/28/21

  • Writer: BPIQ
    BPIQ
  • Jul 28, 2021
  • 3 min read

$XBI $127.28 +3.50%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$VIR +1.70% GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab source


Pipeline Updates

$MYOV -6.0% Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates source


$ALXO +3.3% ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma source


$KPTI +3.7% Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis source


$MDWD -2.0% MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study source


$IMAB +21.5% I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China source


$XOMA +1.3% U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA’s Licensed anti-TGFβ Asset NIS793 source


$ABEO +2.4% Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) source


$MRSN +0.70% Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer source


$RPHM -1.70% Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study source


$PDSB +8.4% PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences source


$BPMC +1.50% MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development source


$NOVN +- 0.0% Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum source


$ZYME -0.40% Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy source


$ARCT -0.40% Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency source


$HCM +14.7% HUTCHMED Reports 2021 Interim Results and Provides Business Updates source


$ABEO +2.40% Abeona Therapeutics Reports Second Quarter Financial Results source


$URGN +2.6% UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel source


$RYTM +3.6% Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome source


$VNDA +1.2% Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results source


$VKTX +3.0% Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update source


$MRKR +4.3% Marker Therapeutics Announces Opening Of New Cgmp Manufacturing Facility source


$PTGX +3.3% Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists source


$HRTX +3.5% Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery source


$FUSN +3.3% Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3 source


$PTCT +1.1% Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™ source



Financial Updates

$XLRN +6.7% ACCELERON ANNOUNCES SECOND QUARTER 2021 REBLOZYL® NET SALES source


$OPTN +4.2% Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million source


$AGEN +5.6% MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering source



Posted by JM

 
 
 

Comments

bottom of page